IL158071A0 - Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer - Google Patents
Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancerInfo
- Publication number
- IL158071A0 IL158071A0 IL15807102A IL15807102A IL158071A0 IL 158071 A0 IL158071 A0 IL 158071A0 IL 15807102 A IL15807102 A IL 15807102A IL 15807102 A IL15807102 A IL 15807102A IL 158071 A0 IL158071 A0 IL 158071A0
- Authority
- IL
- Israel
- Prior art keywords
- health
- related quality
- progression
- patients
- disease
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002349 favourable effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/832,752 US20030022811A1 (en) | 2001-04-11 | 2001-04-11 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US11848602A | 2002-04-08 | 2002-04-08 | |
| PCT/US2002/011397 WO2002085351A1 (en) | 2001-04-11 | 2002-04-11 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158071A0 true IL158071A0 (en) | 2004-03-28 |
Family
ID=26816420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15807102A IL158071A0 (en) | 2001-04-11 | 2002-04-11 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1379238A1 (enExample) |
| JP (1) | JP2005503339A (enExample) |
| CN (1) | CN1514727A (enExample) |
| AR (1) | AR033465A1 (enExample) |
| BR (1) | BR0205970A (enExample) |
| CA (1) | CA2442591A1 (enExample) |
| IL (1) | IL158071A0 (enExample) |
| MX (1) | MXPA03009277A (enExample) |
| PE (1) | PE20021032A1 (enExample) |
| WO (1) | WO2002085351A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| WO2004100991A1 (en) * | 2003-05-15 | 2004-11-25 | Universite Catholique De Louvain | Use of endothelin-1 antagonists for improving cancer therapy |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| JP2009537535A (ja) * | 2006-05-15 | 2009-10-29 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | エンドセリンアンタゴニストの投与を含む睡眠時無呼吸を治療するための方法および組成物 |
| JP2010536880A (ja) | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
| CN117751099A (zh) * | 2021-08-05 | 2024-03-22 | 中国药科大学 | 酰胺类化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL342500A1 (en) * | 1997-08-04 | 2001-06-04 | Abbott Lab | Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists |
-
2002
- 2002-04-11 CN CNA028116720A patent/CN1514727A/zh active Pending
- 2002-04-11 BR BR0205970-3A patent/BR0205970A/pt not_active IP Right Cessation
- 2002-04-11 IL IL15807102A patent/IL158071A0/xx unknown
- 2002-04-11 WO PCT/US2002/011397 patent/WO2002085351A1/en not_active Ceased
- 2002-04-11 AR ARP020101335A patent/AR033465A1/es not_active Application Discontinuation
- 2002-04-11 JP JP2002582924A patent/JP2005503339A/ja active Pending
- 2002-04-11 CA CA002442591A patent/CA2442591A1/en not_active Abandoned
- 2002-04-11 MX MXPA03009277A patent/MXPA03009277A/es unknown
- 2002-04-11 EP EP02726727A patent/EP1379238A1/en not_active Ceased
- 2002-04-11 PE PE2002000305A patent/PE20021032A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2442591A1 (en) | 2002-10-31 |
| JP2005503339A (ja) | 2005-02-03 |
| AR033465A1 (es) | 2003-12-17 |
| BR0205970A (pt) | 2003-09-30 |
| MXPA03009277A (es) | 2004-03-10 |
| PE20021032A1 (es) | 2002-11-12 |
| CN1514727A (zh) | 2004-07-21 |
| EP1379238A1 (en) | 2004-01-14 |
| WO2002085351A1 (en) | 2002-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002243495A1 (en) | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer | |
| EP1594883A4 (en) | COVALENT MODIFICATION OF RNA FOR DISTRIBUTION IN VITRO / I AND IN VIVO / I | |
| AU2003275029A8 (en) | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues | |
| EP1587837A3 (en) | Prostate cancer diagnosis and treatment | |
| SI1678194T1 (sl) | Modulacija sinteze hialuronana in degradacija pri zdravljenju bolezni | |
| IL159785A0 (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
| IL158071A0 (en) | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | |
| AU2001240909A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| EP1294949A4 (en) | HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON | |
| AU2002257139A1 (en) | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | |
| HK1061650A (en) | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | |
| AU2004229218B2 (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
| AU2003250912A1 (en) | Agents and methods for diagnosis and therapy of cancer and cancer risk assessment | |
| AU2002251367A1 (en) | Proteins and genes for diagnosis and treatment of erbb2-related cancer | |
| AU4135600A (en) | Prostate cancer associated human fibronectin gene and biallelic markers | |
| AU2003263036A8 (en) | Span-xb gene and protein for the diagnosis and treatment of cancer | |
| AU2003290988A8 (en) | Levels of pin1 in normal and cancerous tissue | |
| AU2003254145A1 (en) | Disposable front opening brief with pre-selected pad shape and location | |
| AU2002329000A1 (en) | Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1 | |
| AU2002310470A1 (en) | Use of ribonuclease l in diagnosis of cancer | |
| AUPR956701A0 (en) | Cancer diagnosis and therapy ii | |
| AU2002345407A1 (en) | Human cervical cancer 5 protooncogene and protein encoded therein | |
| AU2000280393A1 (en) | Use of mutations of MEC-1 and its related genes in the identification of compounds for treatment of disease | |
| AU2002345393A1 (en) | Human cervical cancer 7 proto-oncogene and protein encoded therein | |
| AU2002345394A1 (en) | Human cervical cancer 2 proto-oncogene and protein encoded therein |